Every Form 4 that Coherus Oncology, Inc. (CHRS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CHRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CHRS filings page.
Coherus Oncology director Ali J. Satvat received new equity awards. On June 5, 2026, he was granted 30,000 restricted stock units, each convertible into one share of common stock upon vesting. According to the terms, all RSUs vest 100% on the one-year anniversary of June 3, 2026, subject to his continued service.
He also received a stock option for 60,000 shares of common stock at an exercise price of $1.45 per share. This option vests and becomes fully exercisable on June 3, 2027, conditional on his continued service with the company, and expires on June 5, 2036.
Coherus Oncology, Inc. reported that director Rita A. Karachun received equity compensation on June 5, 2026. She was granted 30,000 restricted stock units (RSUs), each convertible into one share of common stock upon vesting, with 100% of the RSUs vesting on the one year anniversary of June 3, 2026, subject to her continued service. She was also granted a stock option for 60,000 shares of common stock at an exercise price of $1.45 per share, which vests and becomes exercisable in full on June 3, 2027, subject to continued service. Following these awards, she holds 30,000 shares of common stock and 60,000 stock options directly.
Coherus Oncology, Inc. director Newcomer Lee Nisley reported compensation-related equity grants. The reporting person received 30,000 shares of Common Stock, which footnotes describe as restricted stock units (RSUs) that convert into one share of common stock per unit upon vesting. All 30,000 RSUs vest on the one-year anniversary of June 3, 2026, contingent on continued service. In addition, the reporting person was granted 60,000 stock options with an exercise price of $1.45 per share, expiring on June 5, 2036. These options vest and become exercisable for all 60,000 underlying shares of Common Stock on June 3, 2027, also subject to continued service with the company.
Coherus Oncology, Inc. director Ryan Michael Lee reported receiving new equity-based compensation. He was granted 30,000 restricted stock units (RSUs), each representing one share of common stock upon vesting, and now holds 30,000 common shares directly after this award.
According to the filing, 100% of these RSUs will vest on the one-year anniversary of June 3, 2026, assuming he continues his service with the company. Lee also received stock options for 60,000 shares of common stock at an exercise price of $1.45 per share, which vest and become exercisable in full on June 3, 2027, subject to continued service.
Coherus Oncology, Inc. director Jill O'Donnell-Tormey reported equity awards in the form of common stock and stock options. She received 30,000 shares of Common Stock as restricted stock units, at no purchase price, with 30,000 shares held directly after this grant.
She was also granted stock options for 60,000 shares of Common Stock with an exercise price of $1.45 per share, expiring on June 5, 2036. According to the footnotes, the 30,000 RSUs vest in full on the one year anniversary of June 3, 2026, and the 60,000 options vest and become exercisable in full on June 3, 2027, in each case subject to her continued service with the company.
Coherus Oncology, Inc. director Mats Wahlstrom reported equity awards consisting of common stock and stock options as compensation. He received 30,000 shares of Common Stock that constitute restricted stock units, each converting into one share upon vesting. These RSUs vest 100% on the one-year anniversary of June 3, 2026, contingent on his continued service. He was also granted stock options for 60,000 shares of Common Stock at an exercise price of $1.45 per share, vesting in full on June 3, 2027, also subject to continued service, and expiring on June 5, 2036. Following these awards, Wahlstrom holds 30,000 shares of Common Stock directly and 60,000 stock options.
Coherus Oncology director Charles W. Newton reported equity compensation grants. He received 30,000 shares of Common Stock in the form of restricted stock units, with one share delivered for each unit upon vesting. The RSUs vest 100% on the one year anniversary of June 3, 2026, contingent on his continued service.
He was also granted stock options for 60,000 shares of Common Stock at an exercise price of $1.45 per share, expiring on June 5, 2036. These options vest and become exercisable in full on June 3, 2027, also subject to his continued service. After these awards, he holds 30,000 shares of Common Stock and 60,000 options directly.
Coherus Oncology Chief Financial Officer granted repriced options
Coherus Oncology, Inc. reported that its Chief Financial Officer, Bryan J. McMichael, received several grants of stock options on May 29, 2026, each with an exercise price of $1.59 per share and expirations on May 29, 2036. These options cover multiple blocks, including grants for 100,000, 30,000, 25,000, 25,000, 25,000, and 15,000 shares of common stock as compensation.
On the same date, the company recorded dispositions of earlier stock options back to the issuer, in matching share amounts but with higher exercise prices ranging from $5.44 to $14.76 per share, reflecting a stockholder-approved option repricing for options previously priced at or above $5. No open‑market purchases or sales of common stock were reported in this filing.
Coherus Oncology, Inc. reported that President & CEO Dennis M. Lanfear received multiple stock option grants covering a total of 3,205,000 shares of common stock at an exercise price of $1.59 per share. These new options replace an equal number of older options with exercise prices ranging from $5.44 to $18.33, which were disposed of back to the company.
Stockholders approved this option repricing on May 29, 2026, and the repricing is conditioned on Lanfear remaining in service through May 29, 2027. One block of options vests in 1/48th monthly installments measured from January 5, 2023, while another block is fully vested and exercisable, aligning his compensation structure more closely with the current share price.
Coherus Oncology President & CEO Dennis M. Lanfear reported new equity awards. On January 23, 2026, he received 375,000 restricted stock units of Coherus Oncology common stock at a price of $0. Each RSU converts into one share, with 50% scheduled to vest on May 20, 2027 and 50% on March 20, 2029, subject to his continued service.
He was also granted a stock option for 750,000 shares of common stock at an exercise price of $2.06 per share, expiring January 23, 2036. The option vests as to one-fourth of the shares on the one-year anniversary of January 23, 2026, and the remainder in equal monthly installments thereafter, contingent on continued service. Following these grants, he holds 1,048,235 shares directly, plus indirect holdings of 432,684 shares through a revocable trust and 86,965 shares through an LLC.
Coherus Oncology, Inc.’s Chief Financial Officer, Bryan J. McMichael, reported new equity awards. On January 22, 2026, he received 112,500 restricted stock units of common stock at $0 per share, bringing his directly held common stock to 133,736 shares. These RSUs vest in two equal parts, with 50% vesting on May 20, 2027 and 50% on March 20, 2029, subject to continued service. He was also granted a stock option for 225,000 shares of common stock at an exercise price of $1.59 per share, all held directly. The option vests 25% on the one-year anniversary of January 22, 2026, and the remainder in equal monthly installments over the following three years.
Coherus Oncology’s Chief Financial Officer reports a small tax-related share withholding. On January 20, 2026, 1,715 shares of Coherus Oncology, Inc. common stock were automatically withheld by the company at $1.55 per share to cover tax liabilities tied to vesting restricted stock units. This was reported under transaction code F, which typically reflects tax withholding rather than an open‑market trade.
After this withholding, the CFO directly beneficially owned 21,236 shares of Coherus common stock. The footnote clarifies that no shares were sold by the reporting person; the shares were retained by the issuer to satisfy taxes due on equity compensation.
Coherus Oncology President & CEO Dennis M. Lanfear reported an automatic share withholding related to equity compensation. On January 20, 2026, the issuer withheld 11,839 shares of common stock at $1.55 per share to cover taxes due on the vesting of restricted stock units, and no shares were sold by Lanfear in this transaction. After this withholding, he beneficially owned 673,235 shares directly, plus 432,684 shares held by the Lanfear Revocable Trust and 86,965 shares held by Lanfear Capital Advisors, LLC, both entities associated with him.